2,3,6-Trimethyl-imidazo<1,2-b>pyridazin | 17412-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,3,6-Trimethyl-imidazo<1,2-b>pyridazin
• 英文别名: 2,3,6-trimethyl-imidazo[1,2-b]pyridazine；2,3,6-Trimethylimidazo[1,2-b]pyridazine
• CAS: 17412-40-7
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: CBYQLDVLMZIWRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160024007A1

  公开（公告）日：2016-01-28

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了八氢环戊吡咯化合物，其结构如下：（结构式表示），其中psi不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C（O）或C（O）NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或（C1-C4烷基）-CO2H，其中当B为CO2H时，A存在且为C（O）；当psi存在时，R6不存在，当psi不存在时，R6存在，或其药学上可接受的盐，用于治疗以视网膜过多脂褐质沉积为特征的疾病。
• OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160046632A1

  公开（公告）日：2016-02-18

  The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.

  本发明提供了包含各种取代的八氢吡咯吡咯化合物，它们的合成方法，制备方法，使用方法，以及它们的组成和配方。
• DIARYL MACROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION, AND USE THEREOF
  申请人：Primegene (Beijing) Co., Ltd.

  公开号：EP3786167A1

  公开（公告）日：2021-03-03

  The present invention provides a compound as represented by formula (1) or a pharmaceutically acceptable salt, a solvate, an active metabolite, apolymorph, an isotope label, an isomer or a prodrug thereof. The present invention also provides a pharmaceutical composition containing the same and the use of the compound and the pharmaceutical composition in preparation of drugs for treating tyrosine kinase-mediated diseases. The compound and the pharmaceutical composition comprising same provided by the present disclosure have significant tyrosine kinase inhibitory activity, can overcome tumor drug resistance, and break through through blood-brain barrier, also have excellent pharmacokinetic properties and excellent oral bioavailability, and can be administered in a small dosage, thereby reducing treatment costs of and possible side effects to a patient. Thus, the application potential is very great.

  本发明提供了一种由式（1）表示的化合物或其药学上可接受的盐、溶液剂、活性代谢物、非多晶型物、同位素标记物、异构体或原药。本发明还提供了含有上述化合物的药物组合物，以及该化合物和药物组合物在制备治疗酪氨酸激酶介导的疾病的药物中的用途。本发明公开的化合物及其药物组合物具有显著的酪氨酸激酶抑制活性，能够克服肿瘤耐药性，突破血脑屏障，还具有优异的药代动力学特性和良好的口服生物利用度，可以小剂量给药，从而降低患者的治疗成本和可能的副作用。因此，其应用潜力非常大。
• IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：EP3233862B1

  公开（公告）日：2019-07-03